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lished algorithm to assess quality. Evaluation criteria included
methodological characteristics (perspective, selection of com-
parators, and modeling framework), health care system charac-
teristics (relevance and applicability of clinical, treatment pattern
and cost data), population characteristics (generalizability), and
implications. RESULTS: Large variation in study quality was
observed, particularly with outcome data and treatment pat-
terns. We found that data on the effectiveness of drugs was typ-
ically extracted from clinical trials that did not include an Asian
population, used inappropriate comparators and involved prac-
tice patterns that were not consistent with standards of care in
Korea. With respect to treatment patterns, the most frequent sit-
uation relied on expert opinion from academic physicians in spe-
cialty practice. The Korean National Health Insurance Claims
Database was a good source of disease speciﬁc costs, but was
rarely used. Furthermore, the database failed to capture non-
covered services. Preference measures, when used, were not
elicited from the Korean population. Most studies (80%) did not
clarify the funding source. CONCLUSIONS: If the Korean eco-
nomic evaluation policy is to provide meaningful data for deci-
sion makers, the quality of cost-effectiveness studies will need 
to improve dramatically. This may involve access to or creation
of better data, more diverse funding, improved training of
researchers and evaluators, and partnerships with technology
manufacturers.
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OBJECTIVES: To implement a computerized, centralized, drug
prior-authorization process in a national managed care organi-
zation to control utilization and expenditures of expensive 
medications and to ensure uniformity of authorization criteria
throughout the organization. METHODS: This program was
implemented in the Leumit Health Fund, a HMO operating in
Israel. The HMO’s Medical Division has formulated a drug
policy mandating prior-approval by the Central Medicines
Department for expensive drugs. Additionally, these products
may only be dispensed from HMO owned and operated phar-
macies. To expedite this authorization process, a special com-
puter program was developed which operates under the HMO’s
electronic patient record (EPR) system. Upon prescribing one of
these drugs, a window automatically appears instructing the
physician to press a function key for transmission of an autho-
rization request to the Medical Division for approval of HMO
coverage. Two lines are provided to enter supplementary infor-
mation. The patient is then given a computer-generated pre-
scription which prior to approval, cannot be dispensed via the
HMO’s pharmacy dispensing program which is integrated with
the EPR. The distribution of drugs requested by class, and pro-
portion of requests rejected for the year 2003 was evaluated. The
aggregate monetary value of the requests denied was evaluated.
RESULTS: Throughout the year 2003, 38,490 requests were 
submitted, 44.88% of which were denied. The distribution 
of requests by drug or drug class was: Antineoplastic and
immunomodulating agents 15.58%; neurologicals (not including
anti-epileptics) 14%; newer insulins and rosiglitazone 12%;
ocular lubricants (for patients not suffering from FD or CF)
10.55%; angiotensin receptor blockers 10.24%; clopidogrel
7.18%; other 30.45%. The annual aggregate potential cost of
requests denied was 82,771,608 New Israel Shekels (1 NIS = 4.6
USD). Requests for antineoplastic and immunomodulating
agents accounted for 36.37% of this sum. CONCLUSIONS: The
system was successfully implemented and facilitated standard-
ized approval criteria on the national level.
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OBJECTIVES: To empirically develop and validate the RxCost
Model, a prospective and concurrent risk assessment model that
uses claims-based diagnostic information to predict future phar-
macy expenditures for a US commercial population. Addition-
ally, we sought to empirically develop, validate, and compare the
Mixed RxCost (MRxCost) Model to explore the gain in predic-
tive power associated with adding drug information to the
RxCost Model. Prescription cost risk assessment models can be
used to proﬁle physician practices or control for comorbidity
burden in economic studies. METHODS: A retrospective longi-
tudinal cohort study using MEDSTAT MarketScan claims data
(1998–2000) for ambulatory persons who were continuously
enrolled for at least 13 months and were 18 to 64 years old was
used. A training sample consisting of over 1.3 million lives was
utilized to develop the models. Model coefﬁcients were devel-
oped from AHRQ clinical classiﬁcation software, clinical expert
panel, and stepwise OLS regression to screen noise variables. A
random holdout sample of 218,383 was utilized to validate the
models and to compare the performance of each model. Measure
of discrimination (R-squared), predictive ratios, and discrimina-
tion for hypothetical physician groups were computed and com-
pared to each other as well as to a Demographic-only model and
the proprietary DCG-HCC model. RESULTS: The R-square
value for the prospective RxCost, the MRxCost Model and the
DCG-HCC using the validation sample was 0.22, 0.34 and 0.16,
respectively and was 0.34 for the concurrent RxCost model. The
RxCost model’s predictive ratio’s varied between 0.93 and 1.05
for clinical subgroups and ranged from 1.03 to 1.04 across hypo-
thetical physician patient groups of size 10 to 500. CONCLU-
SIONS: The RxCost Model was successfully developed and it
outperformed the DCG-HCC model in terms of R-square after
re-calibrating the DCG-HCC model. The MRxCost Model also
proved that supplementing drug information can improve dis-
criminatory power.
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OBJECTIVES: To develop key performance indicators for the
Australian reimbursement system and to facilitate ongoing
analysis of the drug funding environment. METHODS: This
study involved the establishment of a relational database that
captured all relevant data over a 14-year period. This included
details of the Australian Pharmaceutical Beneﬁts Advisory Com-
mittee recommendations, listing criteria, product type, pricing,
type of economic evaluation, and public expenditure by product
type. A series of pricing indexes was also developed. The key
performance indicators are in the process of being developed
with input from industry and Government. These objectives are
consistent with the goals of the Free Trade Agreement between
Australia and the USA. RESULTS: The key performance indica-
